Product image of Glimepirid Stada (Glimepiride) supplied by GNH India

Glimepirid Stada

Active Ingredient:
Glimepiride
Origin:
EU

Glimepirid Stada (Glimepiride)

Glimepirid Stada is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose in adults with type 2 diabetes mellitus. Marketed in the European Union, the product is supplied as tablets for oral administration; specific strengths may vary according to local labeling. It is intended for chronic therapy and should be taken according to a healthcare professional’s prescription.

Manufacturer / TM Owner

Stadapharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glimepirid Stada is indicated for the long‑term control of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and lifestyle measures alone are insufficient. It may be used as monotherapy or in combination with other antidiabetic agents.

  • As initial oral therapy for newly diagnosed type 2 diabetes.
  • As add‑on to metformin when glycemic targets are not met.
  • In combination with a DPP‑4 inhibitor or SGLT2 inhibitor for enhanced glucose lowering.
  • For patients who can tolerate sulfonylureas and have adequate renal function.

Side Effects

Glimepirid Stada can cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common

  • Mild hypoglycemia (especially with missed meals).
  • Nausea or abdominal discomfort.
  • Headache or dizziness.
  • Weight gain.
  • Skin rash or pruritus.

Serious

  • Severe hypoglycemia requiring assistance.
  • Allergic reactions such as angioedema or Stevens‑Johnson syndrome.
  • Hepatic dysfunction.
  • Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).

Precautions & Warnings

Before prescribing Glimepirid Stada, clinicians should evaluate several safety considerations.

  • Assess renal and hepatic function; dose adjustment may be needed.
  • Review history of hypersensitivity to sulfonylureas.
  • Caution in elderly patients due to increased hypoglycemia risk.
  • Avoid use during pregnancy and lactation unless benefits outweigh risks.
  • Monitor blood glucose regularly to detect hypoglycemia.
  • Educate patients on recognizing and managing low blood sugar episodes.

Avoid Interactions

Glimepirid Stada may interact with other medicines, altering its efficacy or safety profile.

Avoid

  • Concurrent use with other sulfonylureas or meglitinides (increased hypoglycemia).
  • Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride levels.
  • MAO‑B inhibitors (e.g., selegiline) which can potentiate hypoglycemic effect.

Use with caution

  • Beta‑blockers (may mask hypoglycemia symptoms).
  • Thiazide diuretics (can affect glucose tolerance).
  • ACE inhibitors or ARBs (monitor renal function).
  • Alcohol (enhances hypoglycemia risk).

Frequently Asked Questions

Glimepirid Stada contains glimepiride, a second‑generation sulfonylurea that stimulates insulin release from pancreatic β‑cells.

It is prescribed for the long‑term control of blood glucose in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient.

Glimepiride binds to the sulfonylurea receptor on pancreatic β‑cells, closing ATP‑sensitive potassium channels, causing depolarization, calcium influx, and increased insulin secretion.

Yes, it may be combined with metformin, DPP‑4 inhibitors, SGLT2 inhibitors, or other agents, but dosage adjustments and monitoring are required.

Common side effects include mild hypoglycemia, nausea, headache, weight gain, and skin rash.

Hypoglycemia is more likely if a dose is taken without adequate food intake, after increased physical activity, or when interacting with other hypoglycemic agents.

The pregnancy category is unknown; it should generally be avoided during pregnancy unless the potential benefit justifies the risk.

Blood glucose levels, renal and hepatic function tests, and, in rare cases, complete blood count for hematologic changes should be monitored.

Elderly patients are more prone to hypoglycemia, so clinicians often start with a lower dose and titrate cautiously.

Alcohol can potentiate hypoglycemia and should be limited; regular meals should be maintained to reduce low‑blood‑sugar risk.

If a dose is missed, it should be taken as soon as remembered unless it is near the time of the next scheduled dose; do not double‑dose.

Weight gain is a reported common side effect, likely related to improved glycemic control and increased insulin levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glimepiride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT